Dramatic response of metaplastic breast cancer to chemo-immunotherapy

Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkabl...

Descripción completa

Detalles Bibliográficos
Autor principal: Adams, Sylvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445614/
https://www.ncbi.nlm.nih.gov/pubmed/28649648
http://dx.doi.org/10.1038/s41523-017-0011-0
_version_ 1783238930473156608
author Adams, Sylvia
author_facet Adams, Sylvia
author_sort Adams, Sylvia
collection PubMed
description Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
format Online
Article
Text
id pubmed-5445614
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-54456142017-06-23 Dramatic response of metaplastic breast cancer to chemo-immunotherapy Adams, Sylvia NPJ Breast Cancer Brief Communication Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor. Nature Publishing Group UK 2017-03-29 /pmc/articles/PMC5445614/ /pubmed/28649648 http://dx.doi.org/10.1038/s41523-017-0011-0 Text en © The Author(s) 2017 This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Brief Communication
Adams, Sylvia
Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_full Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_fullStr Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_full_unstemmed Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_short Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_sort dramatic response of metaplastic breast cancer to chemo-immunotherapy
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445614/
https://www.ncbi.nlm.nih.gov/pubmed/28649648
http://dx.doi.org/10.1038/s41523-017-0011-0
work_keys_str_mv AT adamssylvia dramaticresponseofmetaplasticbreastcancertochemoimmunotherapy

Ejemplares similares